Fosun Pharma's New Oral Drug for Vitiligo Gets Green Light for Phase III Trials

Deep News

Yesterday

Shanghai Fosun Pharmaceutical (Group) Co.,Ltd. has announced that its oral candidate FXS5626 tablets (formerly project code AC-201) have received clinical trial approval from the National Medical Products Administration to proceed with a seamless adaptive Phase II/III study targeting non-segmental vitiligo.

In the competitive landscape, Pfizer's ritlecitinib and InnoCare Pharma's soficitinib are leading the pack in the first tier, having already posted positive Phase II/III results. Fosun Pharma's FXS5626, along with Huadong Medicine's VC005 and Hengrui's amiselimib, are positioned roughly in the second tier of development.

Notably, FXS5626 stands out as the only candidate in China's oral vitiligo pipeline explicitly designated as a dual TYK2/JAK1 inhibitor target.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/news/1108076077"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1108076077\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1108076077?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-09 20:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1108076077","market":"hk","top_or_hot":-1,"title":"Fosun Pharma's New Oral Drug for Vitiligo Gets Green Light for Phase III Trials","media":"Deep News","content":"<p><b>Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.</b> has announced that its oral candidate FXS5626 tablets (formerly project code AC-201) have received clinical trial approval from the National Medical Products Administration to proceed with a seamless adaptive Phase II/III study targeting non-segmental vitiligo.<br><br>In the competitive landscape, Pfizer's ritlecitinib and InnoCare Pharma's soficitinib are leading the pack in the first tier, having already posted positive Phase II/III results. <b>Fosun Pharma</b>'s FXS5626, along with Huadong Medicine's VC005 and Hengrui's amiselimib, are positioned roughly in the second tier of development.<br><br>Notably, FXS5626 stands out as the only candidate in China's oral vitiligo pipeline explicitly designated as a dual TYK2/JAK1 inhibitor target.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fosun Pharma's New Oral Drug for Vitiligo Gets Green Light for Phase III Trials</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFosun Pharma's New Oral Drug for Vitiligo Gets Green Light for Phase III Trials\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-09-09 20:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.</b> has announced that its oral candidate FXS5626 tablets (formerly project code AC-201) have received clinical trial approval from the National Medical Products Administration to proceed with a seamless adaptive Phase II/III study targeting non-segmental vitiligo.<br><br>In the competitive landscape, Pfizer's ritlecitinib and InnoCare Pharma's soficitinib are leading the pack in the first tier, having already posted positive Phase II/III results. <b>Fosun Pharma</b>'s FXS5626, along with Huadong Medicine's VC005 and Hengrui's amiselimib, are positioned roughly in the second tier of development.<br><br>Notably, FXS5626 stands out as the only candidate in China's oral vitiligo pipeline explicitly designated as a dual TYK2/JAK1 inhibitor target.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"600196","symbol_name":"复星医药","start_time":0,"source_url":"","article_id":"1108076077","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1108076077","pubTimestamp":1788956512,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd. has announced that its oral candidate FXS5626 tablets (formerly project code AC-201) have received clinical trial approval from the National Medical...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600196":"复星医药","BK0183":"MSCI概念","BK0096":"民营医院","BK1515":"抗疫概念","BK0239":"医药制造","BK0188":"融资融券","BK1593":"医美概念股","BK0175":"白马股","BK0012":"证金概念","BK0196":"行业龙头","BK0187":"一线龙头","BK0060":"抗癌","02196":"复星医药","BK1191":"制药","BK0028":"国家队"},"translate_title":"复星医药治疗白癜风的口服新药获得III期试验许可","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":1,"02196":1},"content_text":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd. has announced that its oral candidate FXS5626 tablets (formerly project code AC-201) have received clinical trial approval from the National Medical Products Administration to proceed with a seamless adaptive Phase II/III study targeting non-segmental vitiligo.In the competitive landscape, Pfizer's ritlecitinib and InnoCare Pharma's soficitinib are leading the pack in the first tier, having already posted positive Phase II/III results. Fosun Pharma's FXS5626, along with Huadong Medicine's VC005 and Hengrui's amiselimib, are positioned roughly in the second tier of development.Notably, FXS5626 stands out as the only candidate in China's oral vitiligo pipeline explicitly designated as a dual TYK2/JAK1 inhibitor target.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}